Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

AIMS: Sodium glucose co‐transporter 2 (SGLT2) inhibitors reduce several cardiovascular risk factors, including plasma glucose, blood pressure, albuminuria and body weight. Long‐term treatment lowers risks of cardiovascular and renal events. The objective of this post hoc analysis was to determine th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Ohkuma, Toshiaki, Van Gaal, Luc, Shaw, Wayne, Mahaffey, Kenneth W., de Zeeuw, Dick, Matthews, David R., Perkovic, Vlado, Neal, Bruce
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078821/
https://ncbi.nlm.nih.gov/pubmed/31729107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13920
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars